| 臺大學術典藏 |
2020-06-30T08:09:51Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Kang-Yi Su;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; KANG-YI SU; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-06-18T08:25:51Z |
Prolonged virus shedding even after seroconversion in a patient with COVID-19
|
Liu W.-D.;Sui-Yuan Chang;Wang J.-T.;Tsai M.-J.;Hung C.-C.;Hsu C.-L.;Chang S.-C.; Liu W.-D.; SUI-YUAN CHANG; Wang J.-T.; Tsai M.-J.; Hung C.-C.; Hsu C.-L.; Chang S.-C. |
| 臺大學術典藏 |
2020-06-16T06:33:24Z |
Selective growth of silicon nanowires on glass substrate with an ultrathin a-Si:H layer
|
Hsueh, H.T.;Hsueh, T.J.;Chang, S.J.;Hung, F.Y.;Hsu, C.L.;Weng, W.Y.;Liu, C.W.;Lee, Y.H.;Dai, B.T.; Hsueh, H.T.; Hsueh, T.J.; Chang, S.J.; Hung, F.Y.; Hsu, C.L.; Weng, W.Y.; Liu, C.W.; Lee, Y.H.; Dai, B.T.; CHEE-WEE LIU |
| 臺大學術典藏 |
2020-05-26T09:27:07Z |
Advanced non-small cell lung cancer in patients aged 45 years or younger: Outcomes and prognostic factors
|
Yang P.-C.;Yu C.-J;Chih-Hsin Yang;Ho C.-C;Shih J.-Y;Chen K.-Y;Hsu C.-L; Hsu C.-L; Chen K.-Y; Shih J.-Y; Ho C.-C; CHIH-HSIN YANG; Yu C.-J; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:55Z |
Advanced non-small cell lung cancer in the elderly: The impact of age and comorbidities on treatment modalities and patient prognosis
|
Yang P.-C.;Yu C.-J;Chih-Hsin Yang;Shih J.-Y;Chen K.-Y;Chen J.-H;Hsu C.-L; Hsu C.-L; Chen J.-H; Chen K.-Y; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Yu C.-J.;Chih-Hsin Yang;Shih J.-Y;Lin C.-C;Lee J.-H;Chang Y.-L;Su K.-Y;Hsu W.-H;Hsu C.-L;Tsai T.-H;Chen K.-Y;Liao W.-Y;Ho C.-C;Liao B.-C;Yang C.-Y;Lin S.-Y; Lin S.-Y; Yang C.-Y; Liao B.-C; Ho C.-C; Liao W.-Y; Chen K.-Y; Tsai T.-H; Hsu C.-L; Hsu W.-H; Su K.-Y; Chang Y.-L; Lee J.-H; Lin C.-C; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T;Chen J.-S;Liao W.-Y;Ho C.-C;Hsu C.-L;Yang C.-Y;Chen K.-Y;Lee J.-H;Lin Z.-Z;Shih J.-Y;Chih-Hsin Yang;Yu C.-J.; Lin Y.-T; Chen J.-S; Liao W.-Y; Ho C.-C; Hsu C.-L; Yang C.-Y; Chen K.-Y; Lee J.-H; Lin Z.-Z; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:17Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y;Liao W.-Y;Ho C.-C;Chen K.-Y;Tsai T.-H;Hsu C.-L;Su K.-Y;Chang Y.-L;Wu C.-T;Hsu C.-C;Liao B.-C;Hsu W.-H;Lee J.-H;Lin C.-C;Shih J.-Y;Chih-Hsin Yang;Yu C.-J.; Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Su K.-Y; Chang Y.-L; Wu C.-T; Hsu C.-C; Liao B.-C; Hsu W.-H; Lee J.-H; Lin C.-C; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T07:35:13Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y; Yang C.-Y; Liao B.-C; Ho C.-C; Liao W.-Y; Chen K.-Y; Tsai T.-H; Hsu C.-L; Hsu W.-H; Su K.-Y; Chang Y.-L; Lee J.-H; Chia-Chi Lin; Shih J.-Y; Yang J.C; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T07:35:03Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yu C.-J.; Yang J.C.-H; Shih J.-Y; Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Liu Y.-N; Su K.-Y; Chang Y.-L; Wu C.-T; Liao B.-C; Hsu C.-C; Hsu W.-H; Lee J.-H; Chia-Chi Lin |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Su K.-Y; Chang Y.-L; Wu C.-T; Hsu C.-C; Liao B.-C; Hsu W.-H; Lee J.-H; Chia-Chi Lin; Shih J.-Y; Yang J.C.-H; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T01:32:58Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-05-20T05:11:42Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.;Yang J.C.-H.;Shih J.-Y.;Lin Z.-Z.;Lee J.-H.;Chen K.-Y.;Yang C.-Y.;Hsu C.-L.;Ho C.-C.;Liao W.-Y.;Chen J.-S.;YEN-TING LIN; YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-05-18T08:38:54Z |
Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab
|
Hsu C.-L.;Chen K.-Y.;Shuenn-Wen Kuo;Chang Y.-L.; Hsu C.-L.; Chen K.-Y.; SHUENN-WEN KUO; Chang Y.-L. |
| 臺大學術典藏 |
2020-05-12T02:50:18Z |
Efficiency enhancement and sensitive broadband 1Hz ? 1kHz of power generator by recycling vibration energy on Automobile
|
HSUEN-LI CHEN;Ho, C.;Lai, Y.-S.;Liu, J.-M.;Chiu, W.-C.;Hsu, C.-L.;Liu, S.C.;Li, M.;Chen, C.-C.;Gu, M.-H.;Lin, Y.-B.;Chen, H.-L.;Sun, T.-P.;Ko, F.-H.;Wei, M.-Q.; Wei, M.-Q.; Ko, F.-H.; Sun, T.-P.; Chen, H.-L.; Lin, Y.-B.; Gu, M.-H.; Chen, C.-C.; Li, M.; Liu, S.C.; Hsu, C.-L.; Chiu, W.-C.; Liu, J.-M.; Lai, Y.-S.; Ho, C.; HSUEN-LI CHEN |
| 臺大學術典藏 |
2020-04-22T07:09:04Z |
Structural relaxation of adlayers in the presence of adsorbate-induced reconstruction: C60/Cu(111)
|
Tang, T.B.; Lin, K.C.; Hsu, C.-L.; Lin, M.C.; Pai, W.W. |
| 臺大學術典藏 |
2020-04-22T07:09:04Z |
Aperiodic incommensurate phase of a C60 monolayer on Ag(100)
|
Hsu, C.-L.; Pai, W.W. |
| 臺大學術典藏 |
2020-04-22T07:08:56Z |
Ordering of an incommensurate molecular layer with adsorbate-induced reconstruction: C60/Ag(100)
|
Pai, W.; Hsu, C.-L. |
| 臺大學術典藏 |
2020-04-22T07:08:56Z |
Origin of peculiar STM molecular contrast in C60/Ag(100)
|
Pai, W.W.; Hsu, C.-L.; Chiang, C.R.; Chang, Y.; Lin, K.C. |
| 臺大學術典藏 |
2020-04-16T02:34:53Z |
Pulse analysis system with a novice periodic function examination method on sepsis survival prediction
|
Wu, Z.-H.; Yang, C.-J.; Liao, Z.-K.; Lai, F.; Hsu, C.-L.; Sun, W.-Z.; FEI-PEI LAI; Chen, W.;Wu, Z.-H.;Yang, C.-J.;Liao, Z.-K.;Lai, F.;Hsu, C.-L.;Sun, W.-Z.; Chen, W. |
| 臺大學術典藏 |
2020-04-10T12:51:00Z |
Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma
|
Ou D.-L.;Lin Y.-Y.;Hsu C.-L.;Lin Y.-Y.;Chen C.-W.;Yu J.-S.;Miaw S.-C.;Hsu P.-N.;Cheng A.-L.;Chiun Hsu; Ou D.-L.; Lin Y.-Y.; Hsu C.-L.; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; Hsu P.-N.; Cheng A.-L.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-07T07:00:53Z |
Increased Risk of Acute Cholecystitis in Patients With Spinal Cord Injury: A Nationwide Population-Based Cohort Study
|
Hsu C.-L.; Wang M.-T.; Ho Y.-C.; SHIN-LIANG PAN; Hsu C.-L.;Wang M.-T.;Ho Y.-C.;Shin-Liang Pan |
| 臺大學術典藏 |
2020-04-07T07:00:53Z |
Spinal cord injury and Alzheimer's disease risk: A population-based, retrospective cohort study article
|
SHIN-LIANG PAN; Hsu C.-L.; Ho Y.-C.; Yeh T.-S.;Ho Y.-C.;Hsu C.-L.;Shin-Liang Pan; Yeh T.-S. |
| 臺大學術典藏 |
2020-03-31T08:54:40Z |
Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis
|
Yang P.-C.; LI-NA LEE; Hsueh P.-R.; Yu C.-J.; Hsu C.-L.; Tsai T.-H.; Wang J.-T.; Wang J.-Y. |
| 臺大學術典藏 |
2020-03-31T08:54:37Z |
Clinical characteristics and prognosis of nontuberculous mycobacterial lung disease with different radiographic patterns
|
LI-NA LEE; Yu C.-J.; Shu C.-C.; Lee C.-H.; Hsu C.-L.; Wang J.-T.; Wang J.-Y. |
